Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | GOT1 | P17174 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL29368426 | 1.00 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL4774002 | 1.00 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL30354044 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL3139060 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL122876 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL5859456 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL3143295 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL4914143 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL6599516 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL374870 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25062 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| WO-1997032037-A1 | ASSESSMENT OF THE RESPONSIVENESS OF INDIVIDUALS TO MODULATORS OF THE 5-HT2 RECEPTORS, ESPECIALLY THE 5-HT2A RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 1997-09-04 | — | — | WO | claimed |
| EP-0790236-A1 | Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one | PFIZER INC. (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1997021833-A1 | METHOD OF PREDICTING A SUBJECTS RESPONSE TO NEUROLEPTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-19 | — | — | WO | claimed |
| CN-1142945-A | Medcine for curing cerebrovascular disturbance with psychonosema | SUMITOMO PHARMA (JP) | 1997-02-19 | — | — | CN | claimed |
| CN-1033089-C | Process for preparation aryl piperazinyl-heterocyclic compounds | PFIZER (US) | 1996-10-23 | — | — | CN | claimed |
| WO-1996031621-A2 | METHOD FOR DETERMINING THE RESPONSIVENESS OF INDIVIDUALS TO 5-HT2 RECEPTOR MODULATING AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-10 | — | — | WO | claimed |
| EP-0730865-A1 | Use of serotonin and dopamine receptor blockers for the treatment of mental disorders associated with cerebrovascular disease | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-09-11 | — | — | EP | claimed |
| US-5338846-A | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt | PFIZER INC. (US) | 1994-08-16 | — | — | US | claimed |
| EP-0586191-A1 | Monohydrate of 5-(2-(4-(1,2 Benzisothiazol-3-YL)-1-Piperazinyl)-Ethyl)-6-Chloro-1,3-Dihydro-2H-indol-2-one Hydrochloride | PFIZER INC. (US) | 1994-03-09 | — | — | EP | claimed |
| EP-0584903-A1 | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1994-03-02 | — | — | EP | claimed |